161 related articles for article (PubMed ID: 8215288)
1. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
Dever LL; Jorgensen JH; Barbour AG
Antimicrob Agents Chemother; 1993 Aug; 37(8):1704-6. PubMed ID: 8215288
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Visalli MA; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.
Cinco M; Padovan D; Stinco G; Trevisan G
Antimicrob Agents Chemother; 1995 May; 39(5):1185-6. PubMed ID: 7625812
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
Cent Eur J Public Health; 2017 Dec; 25(4):282-286. PubMed ID: 29346850
[TBL] [Abstract][Full Text] [Related]
5. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Ednie LM; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1950-2. PubMed ID: 8843313
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
Dever LL; Jorgensen JH; Barbour AG
J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Sep; 41(9):1867-70. PubMed ID: 9303375
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
[TBL] [Abstract][Full Text] [Related]
9. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.
Levin JM; Nelson JA; Segreti J; Harrison B; Benson CA; Strle F
Antimicrob Agents Chemother; 1993 Jul; 37(7):1444-6. PubMed ID: 8363373
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.
Tateda K; Ishii Y; Matsumoto T; Furuya N; Nagashima M; Matsunaga T; Ohno A; Miyazaki S; Yamaguchi K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2271-5. PubMed ID: 8891128
[TBL] [Abstract][Full Text] [Related]
12. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V; Thorburn CE; Knott SJ; Woodnutt G
Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
Welsh L; Gaydos C; Quinn TC
Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907
[TBL] [Abstract][Full Text] [Related]
14. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583
[TBL] [Abstract][Full Text] [Related]
15. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Jones RN; Doern GV; Gerlach EH; Hindler J; Erwin ME
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):243-9. PubMed ID: 7924221
[TBL] [Abstract][Full Text] [Related]
16. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.
Preac-Mursic V; Wilske B; Schierz G; Süss E; Gross B
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):651-3. PubMed ID: 2550233
[TBL] [Abstract][Full Text] [Related]
17. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.
Metzler K; Drlica K; Blondeau JM
J Antimicrob Chemother; 2013 Mar; 68(3):631-5. PubMed ID: 23169894
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.
Mehaffey PC; Putnam SD; Barrett MS; Jones RN
J Clin Microbiol; 1996 Feb; 34(2):479-81. PubMed ID: 8789046
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.
Dever LL; Torigian CV; Barbour AG
Antimicrob Agents Chemother; 1999 Jul; 43(7):1773-5. PubMed ID: 10390242
[TBL] [Abstract][Full Text] [Related]
20. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.
Tateda K; Ishii Y; Matsumoto T; Kobayashi T; Miyazaki S; Yamaguchi K
J Infect Chemother; 2000 Mar; 6(1):1-7. PubMed ID: 11810524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
